![]() | |
| Clinical data | |
|---|---|
| Trade names | Geref, Gerel |
| Other names | GRF 1–29 |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | Injection |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C149H246N44O42S |
| Molar mass | 3357.93 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Sermorelin acetate (INN; brand names Geref, Gerel), also known as GHRH (1-29), is a peptide analogue of growth hormone-releasing hormone (GHRH) which is used as a diagnostic agent to assess growth hormone (GH) secretion for the purpose of diagnosing growth hormone deficiency. It is a 29-amino acid polypeptide representing the 1–29 fragment from endogenous human GHRH, thought to be the shortest fully functional fragment of GHRH.[1][2]
See also
References
- ↑ Prakash A, Goa KL (August 1999). "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency". BioDrugs. 12 (2): 139–57. doi:10.2165/00063030-199912020-00007. PMID 18031173.
- ↑ Pharmacology (Rang, Dale, Ritter & Moore, ISBN 0-443-07145-4, 5th ed., Churchill Livingstone 2003).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
